Oculis Holding AG announced that its Q3 2025 earnings will be released on November 10, 2025. The company, a clinical‑stage biopharmaceutical focused on ophthalmic and neuro‑ophthalmic diseases, will provide updated financials and guidance for the quarter.
The announcement follows a period of significant clinical development activity. In Q3 2024, Oculis reported a net loss of $23.3 million, while the year‑to‑date loss for Q2 2025 reached $67.9 million, compared with $41.5 million for the same period in 2024. Research and development expenses were $18.1 million in Q2 2025, virtually unchanged from the $18.2 million spent in Q2 2024, and general‑and‑administrative costs rose to $7.4 million from $6.9 million.
The company’s earnings are expected to reflect the ongoing investment in its pipeline, which includes the lead candidates OCS‑01 (diabetic macular edema), OCS‑02 (dry eye disease), and OCS‑05 (acute optic neuritis). Management has emphasized a strong focus on execution to advance these assets, noting that clinical development costs remain the primary driver of the company’s operating expenses.
Oculis recently completed a $100 million equity financing in early 2025 and an additional $110 million ordinary‑share offering in late October, bolstering its cash runway into the second half of 2026 and potentially into early 2028. CEO Riad Sherif stated, “We maintain a strong focus on execution to advance our portfolio of highly differentiated assets in areas with significant unmet medical needs.”
Investors and analysts will look to the November 10 release for guidance on cash runway, pipeline milestones, and cost management, as the company continues to navigate the competitive landscape of ophthalmic therapeutics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.